Cardiogenic Shock Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight

DelveInsight's "Cardiogenic Shock Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Cardiogenic Shock, historical and forecasted epidemiology as well as the Cardiogenic Shock market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Cardiogenic Shock, offering comprehensive insights into the Cardiogenic Shock revenue trends, prevalence, and treatment landscape. The report delves into key Cardiogenic Shock statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Cardiogenic Shock therapies. Additionally, we cover the landscape of Cardiogenic Shock clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Cardiogenic Shock treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Cardiogenic Shock space.

To Know in detail about the Cardiogenic Shock market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cardiogenic Shock Market Forecast
https://www.delveinsight.com/sample-request/cardiogenic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Cardiogenic Shock Market Report:
• The Cardiogenic Shock market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In November 2025, 4TEEN4 Pharmaceuticals GmbH ("4TEEN4") has announced an increase of its Series C financing round to €55 million ($64 million), with participation from both existing and new investors. The funds will support the continued development of procizumab in patients experiencing shock primarily due to cardiogenic events. Additionally, the capital will help expand the PROCARD 2a study across Europe and facilitate planned growth in the U.S., enhancing patient access to procizumab and strengthening operational readiness ahead of the pivotal trial. Procizumab, 4TEEN4's proprietary monoclonal antibody, targets circulating dipeptidyl peptidase 3 (cDPP3), a cardiac depression factor and key pathological driver in shock, a life-threatening condition marked by acute circulatory failure from end-stage disease or sudden critical events.
• In August 2025, Windtree announced that interim Phase II data for istaroxime in SCAI Stage C cardiogenic shock will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025.
• In July 2025, 4TEEN4 Pharmaceuticals initiated the Phase Ib/IIa PROCARD1 trial of procizumab in cardiogenic shock and published European Journal of Heart Failure data showing the drug's favorable tolerability, effective cDPP3 blockade, and rapid shock reversal within 48 hours without immediate adverse events.
• In June 2025, Windtree announced the publication of its Phase II SEISMiC B study on early cardiogenic shock in the Journal of Heart and Lung Transplantation, reporting the safety and efficacy of intravenous istaroxime (up to 60 hours) in patients with poor cardiac function and low blood pressure requiring rapid treatment.
• In May 2025, Windtree presented data from the Phase IIb SEISMiC Extension study of istaroxime in early cardiogenic shock at the European Society of Cardiology Heart Failure 2025 Conference.
• In April 2025, 4TEEN4 reported completion of the Phase I trial, confirming good tolerability across all tested doses, no significant safety concerns, and a favorable safety profile. The results supported advancement into the Phase Ib/IIa study to further evaluate its therapeutic potential in circulatory failure
• Key Cardiogenic Shock Companies: Windtree Therapeutics, 4TEEN4 Pharmaceuticals, and others
• Key Cardiogenic Shock Therapies: Istaroxime, Procizumab (PCZ, AK1967), and others
• The Cardiogenic Shock market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cardiogenic Shock pipeline products will significantly revolutionize the Cardiogenic Shock market dynamics.
• In the U.S., approximately 80% of cardiogenic shock cases occur after an acute myocardial infarction (AMI), usually due to left ventricular failure, while the remaining 20% are caused by AMI-related complications such as acute mitral regurgitation, ventricular septal defect, or free wall rupture. Right heart failure, often associated with right ventricular AMI, can also contribute to the condition.
• In 2018, the rate of hospitalizations for cardiogenic shock in the U.S. was 408 per 100,000 people, with 103 per 100,000 attributed to AMI-related cardiogenic shock and 258 per 100,000 to non-AMI-related cardiogenic shock.
• According to secondary sources, in 2017, Germany reported a cardiogenic shock incidence of 53.7 hospitalizations per 100,000 person-years.
• In Italy, cardiogenic shock represented 2.17% of all general intensive care unit admissions, with causes including left heart failure (47.5%), AMI (32.6%), right heart failure (4.6%), and biventricular failure (4.8%).
• In Japan, the causes of cardiogenic shock were reported as AMI 77.4%, heart failure 10.9%, arrhythmia 4.5%, valvular disease 2.7%, fulminant myocarditis 2.5%, and pulmonary embolism 2.0%.

Cardiogenic Shock Overview
Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's needs, leading to low blood pressure, reduced oxygen delivery to organs, and potential organ failure. It most commonly occurs after a severe heart attack, but can also result from heart failure, cardiomyopathy, or severe arrhythmias. Symptoms include rapid breathing, weak pulse, cold or clammy skin, confusion, and low urine output. Immediate medical intervention, often involving medications, mechanical support, or procedures to restore heart function, is critical for survival.

Get a Free sample for the Cardiogenic Shock Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/cardiogenic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cardiogenic Shock Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cardiogenic Shock Epidemiology Segmentation:
The Cardiogenic Shock market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Incident Cases of Cardiogenic Shock
• Etiology-specific Cases of Cardiogenic Shock
• Treated Cases of Cardiogenic Shock

Download the report to understand which factors are driving Cardiogenic Shock epidemiology trends @ Cardiogenic Shock Epidemiology Forecast
https://www.delveinsight.com/sample-request/cardiogenic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cardiogenic Shock Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cardiogenic Shock market or expected to get launched during the study period. The analysis covers Cardiogenic Shock market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cardiogenic Shock Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cardiogenic Shock Therapies and Key Companies
• Istaroxime: Windtree Therapeutics
• Procizumab (PCZ, AK1967): 4TEEN4 Pharmaceuticals
• AK1967 (Procizumab): 4TEEN4 Pharmaceuticals GmbH

Discover more about therapies set to grab major Cardiogenic Shock market share @ Cardiogenic Shock Treatment Landscape
https://www.delveinsight.com/sample-request/cardiogenic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cardiogenic Shock Market Drivers
• Rising prevalence of acute myocardial infarction (AMI) and heart failure globally.
• Increasing geriatric population susceptible to cardiovascular diseases.
• Advancements in cardiogenic shock management technologies and devices, including mechanical circulatory support systems.
• Growing adoption of innovative drugs for improving cardiac output and hemodynamic stability.
• Expansion of hospital infrastructure and specialized cardiac care units.
• Increased awareness and early diagnosis through advanced monitoring and imaging techniques.

Cardiogenic Shock Market Barriers
• High treatment costs, limiting access to advanced therapies in developing regions.
• Complexity of managing multi-organ dysfunction associated with cardiogenic shock.
• Limited availability of skilled healthcare professionals in some regions.
• Regulatory challenges and lengthy approval processes for new devices and therapies.
• Risk of complications from invasive procedures, including mechanical support devices.
• Low patient adherence to long-term therapies and follow-up care.
• Unpredictable patient outcomes, making standardization of treatment difficult.

Scope of the Cardiogenic Shock Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cardiogenic Shock Companies: Windtree Therapeutics, 4TEEN4 Pharmaceuticals, and others
• Key Cardiogenic Shock Therapies: Istaroxime, Procizumab (PCZ, AK1967), and others
• Cardiogenic Shock Therapeutic Assessment: Cardiogenic Shock current marketed and Cardiogenic Shock emerging therapies
• Cardiogenic Shock Market Dynamics: Cardiogenic Shock market drivers and Cardiogenic Shock market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cardiogenic Shock Unmet Needs, KOL's views, Analyst's views, Cardiogenic Shock Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.